Resistance to acetylsalicylic acid and clopidogrel

H. Mani; E. Lindhoff-Last

doi:10.1055/s-0037-1617071

Hämostaseologie, Table of Contents

Hamostaseologie 2006; 26(03): 229-238
DOI: 10.1055/s-0037-1617071

Original Article

Schattauer GmbH

Resistenz gegen Azetylsalizylsäure und Clopidogrel

Aktuelles WissenResistance to acetylsalicylic acid and clopidogrelcurrent status

H. Mani

¹Schwerpunkt Angiologie /Hämostaseologie, Medizinische Klinik III, Zentrum der Inneren Medizin, Johann-Wolfgang-Goethe-Universität, Frankfurt am Main

,

E. Lindhoff-Last

¹Schwerpunkt Angiologie /Hämostaseologie, Medizinische Klinik III, Zentrum der Inneren Medizin, Johann-Wolfgang-Goethe-Universität, Frankfurt am Main

› Author Affiliations

Abstract

PDF Download

Zusammenfassung

Resistenz gegen Azetylsalizylsäure (ASS) bzw. Clopidogrel wird vom klinischen Gesichtspunkt als Unvermögen des Wirkstoffs angesehen, rezidivierende arterielle Gefäßverschlüsse zu verhindern. Aus laborchemischer Sicht hingegen wird die Non-Response gegenüber ASS und Clopidogrel als das Ausbleiben eines erwarteten Effektes in verschiedenen Thrombozytenfunktionstestsystemen beschrieben. Etablierte Thrombozytenfunktionsteste ermöglichen meist keine spezifischen Aussagen über die Thrombozytenaggregationshemmung durch ASS oder Clopidogrel. Wünschenswert wäre, die ASS- und Clopidogrel-Non-Response mit Plättchenfunktionstesten derart zu ermitteln, dass isoliert die spezifischen Effekte dieser Arzneimittel erfasst werden. Im Idealfall könnte eine solche Labordiagnostik helfen, klinische Ereignisse aufgrund eines Therapieversagens im Vorfeld zu verhindern. Studien, die eine Prävalenz von 5 bis 59% für die ASS- oder Clopidogrel-Non-Response angeben, geben erste Hinweise dafür, dass der Nachweis einer laborchemischen ASS- oder Clopidogrel-Non-Response mit dem nachfolgendem Auftreten vaskulärer Reereignisse assoziiert sein könnte. Allerdings sind diese Studien durch zu geringe Fallzahlen, fehlende Standardisierung der Labormethoden und sehr differente Einschlusskriterien in ihrer Aussagekraft limitiert. Deshalb bleibt die klinische Relevanz laborchemisch nachgewiesener ASS- oder Clopidogrel- Resistenz unklar und sollte umgehend in prospektiven Multizenterstudien geklärt werden. Die individuellen Ursachen einer reduzierten oder ausbleibenden Wirkung von ASS oder Clopidogrel können multifaktoriell sein. Die Mechanismen der ASS- bzw. Clopidogrel- Resistenz sind weitgehend ungeklärt.

Summary

Resistance to acetylsalicylic acid (ASA) or clopidogrel is understood from the clinical point of view as failure of the drugs to prevent recurrent vascular occlusions. Non-response to ASA and clopidogrel is defined from the laboratory aspect as an inability to cause in vitro detectable platelet function inhibition. It would be beneficial to monitor non-response to ASA or clopidogrel with platelet function methods, which detect the specific effect of these drugs, and thus prevent clinical events caused by failure of therapy. Non-response to ASA and clopidogrel are detected with different platelet function methods, which are not always clinically standardized and are assessing only the global platelet function and not the specific drug effect. Although various studies reporting 5 to 59% non-response for both drugs, support a clinical relevance of ASA and clopidogrel non-response, well-designed clinical prospective trials are required to identify patients with antiplatelet drug resistance. Furthermore, mechanisms explaining this phenomenon of drug resistance are still unknown.

Schlüsselwörter

Azetylsalizylsäure-Resistenz - Clopidogrel-Resistenz - Thromboyztenfunktionsteste

Keywords

ASA resistance - clopidogrel resistance - platelet function tests

PDF (1205 kb)

References

Literatur
1 ACC/AHA e2005 practice.. Guidelines for the Management of Patients With Peripheral Arterial Diseas (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). Circulation 2006; 113: 1474-547.
2 Anderssen K, Hurlen M, Arnesen H. et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108: 37-42.
3 Antithrombotic Trialists´Collaboration.. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324 7329 71-86.
4 Aspirin Trialist´Collaboration.. Collaborative overview of randomized trials of antiplatelet therapy – I: prevention of death, myocardial infarction, stroke by prolonged antiplatelt therapy in various categories of patients. Br Med J 1994; 308: 81-106.
5 Barragan P, Bouvier JL, Roquebert PO. et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
6 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9.
7 Born GVR, Dearnley R, Foulks JG. Quantification of the morphological reaction of platelets to aggregating agents and its reversal by aggregation inhibitors. J Physiol 1978; 280: 193-212.
8 Bornstein NM, Karepov VG, Aronvich BD. et al. Failure of aspirin treatment after stroke. Stroke 1994; 25: 275-7.
9 Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: Implications for use of ASA clinically. Can J Cardiol 1995; 11: 221-7.
10 Cambria-Kiely JA, Ghandi PJ. Aspirin resistance and Genetic polymorphisms. J Thromb Thrombol 2002; 14: 51-8.
11 CAPRIE Steering Committee.. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
12 Cassar K, Baccgoo P, Ford I. et al. Variability in responsiveness to clopidogrel in patients with intermittent claudication. Eur J Vasc Endovasc Surg. 2006 epub ahead of print.
13 Catella-Lawson F, Reilly MP, Kapoor SC. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-45.
14 Chakroun T, Gerotziafas G, Robert F. et al. In vitro aspirin resistance detected by the PFA-100 closure time: pivotal role of plasma of von Willebrand factor. Br J Haematol 2004; 124: 80.
15 CHARISMA investigators.. Clopiodgrel and Aspirin versus Aspirin alone for the Prevention of Atherothrombotic Events. N Engl J Med 2006; 354: 1706-17.
16 Chen WH, Lee PY, Ng W. et al. Aspirin resistance is associated with high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel treatment. J AmColl Cardiol 2004; 43: 1222-6.
17 Coakley M, Self R, Marchant W. et al. Use of the platelet function analyser to quantify the effect of low dose aspirin in patients with ischemic heart disease. Anaestesia 2005; 60: 1173.
18 Coma-Canella I, Velasco A, Castano S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 2005; 101: 71-6.
19 Cotter G, Shemesh E, Zehavi M. et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J 2004; 147: 293-300.
20 Cuisset T, Frere C, Quilici J. et al. High post-treatment platelet reactivity identifiedlow-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542-9.
21 Diener HC, Bogousslavskey J, Brass LM. et al. The MATCH investigators.. Aspirin and Clopidogrel compared with Clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high risk patients (MATCH): randomised, doubleblind, placebo controlled trial. Lancet 2004; 364: 331-7.
22 Eikelboom JW, Hirsh J, Weitz J. et al. Aspirin resistance and the risk of mycardial infarction, stroke or cardiovascular death in patients at high risk of cardiovascular outcomes. Circulation 2002; 105: 1650-5.
23 EUROCISS Working Group. Coronary and cerebrovascular population-based registers in Europe: Are morbidity indicators comparable? Results from the EUROCISS Project. Eur J Public Health. 2003 13. Supplement 1.
24 Fontana P, Berdague P, Reny JL. Haemostasis. Aspirin and clopidogrel platelet resistance. Rev Med Siusse 2006; 2: 25-9.
25 Fox K, Metha S, Peters R. et al. Benefits and risk of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elavation acute coronary syndrome: the CURE trial. Circulation 2004; 110: 1202-8.
26 Geiger J, Teichmann L, Grossmann R. et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005; 51: 957-65.
27 Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients; evidence of nonresponse in a subpopulation of treated patients. Thromb Res 1991; 63: 587-93.
28 Grotemeyer KH, Scharafinski HW, Husted IW. Two-year follow-up of aspirin responder and aspirin- nonresponder. A pilot study including 180 poststroke patients. Thomb Res 1993; 71: 397-403.
29 Grundmann K, Jaschonek K, Kleine B. et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 63-6.
30 Gum PA, Kottke Merchant K, Poggio ED. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5.
31 Gum PA, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-5.
32 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
33 Hanjis C, Frishman WH, Lerner RG. Aspirin resistance: mechanisms and clinical implications. Cardiol Rev 2006; 14: 18-25.
34 Harrison P, Robinson MS, Mackie I. et al. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinol 1999; 10: 25-31.
35 Harrison P, Segal H, Blasbery K. et al. Screening for aspirin responsiveness after transient ischemic attack and stroke. Stroke 2005; 36: 1001-5.
36 Haubelt H, Simon M, Anders P. et al. Plättchenfunktionstests zum Monitoring der Azetysalicylsäure. Hämostaseologie 2004; 24: 196-202.
37 Helgasson CM, Bolin KM, Hoff JA. et al. Development of aspirin resistance in persons with previous ischaemic stroke. Stroke 1994; 25: 2331-6.
38 Helgason CM, Tortorice KL, Winkler SR. et al. Aspirin response and failure in cerebral infarction. Stroke 1993; 24: 345-50.
39 Hung J, Lam JYT, Lacoste L. et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-6.
40 Ivandic BT, Schlick P, Staritz P. et al. Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y₁₂ receptor. Clin Chem 52 3: 383-8.
41 Koscielny J, Meyer O, Kiesewetter H. et al. Plättchenreaktivitätsindex nach Grotemeyer. Hämostaseologie 2004; 24: 207-10.
42 Lau W, Gurbel PA, Watkins PB. et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-71.
43 Lau WC, Waskell LA, Watkins PB. et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-7.
44 Lev EI, Patel RT, Maresh KJ. et al. Aspirin and clopidogrel drug response in patients undergoing percutaneus coronary intervention. J Am Coll Cardiol 2006; 47: 27-33.
45 Macchi L, Christiaens L, Brabant S. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45-9.
46 Macci L, Sorel N, Christiaens L. Aspirin resistance: definitions, mechanisms, prevalence, and clinical signifiance. Curr Pharm Des 2006; 12: 251-8.
47 Mani H, Linnemann B, Luxembourg B. et al. Response to aspirin and clopidogrel monitored with different platelet function methods. Platelets. 2006 in press.
48 Mani H, Luxembourg B, Kläffling C. et al. Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J Clin Pathol 2005; 58: 747-50.
49 Maree AO, Curtin RJ, Dooley M. et al. Platelet response tolow-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46: 1258-63.
50 Mason PJ, Freedman JE, Jacobs AK. Aspirin resistance: current concepts. Rev Cardiovasc Med 2004; 5: 156-63.
51 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
52 Matzdorff A. Platelet function tests and flow cytometry to monitor antiplatelet therapy. Sem Thromb Hemost 2005; 31: 393-9.
53 McKee SA, Sane DC, Deliagyris N. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88: 711-5.
54 Mueller MR, Salat A, Stangl P. et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-7.
55 Muller I, Seyfarth M, Rudiger S. et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-3.
56 Nowak G. Monitoring von Plättchenfunktionsinhibitoren. Hämostaseologie 2004; 24: 191-5.
57 Ortel TL, James EH, Thames KD. et al. Assessment of primary hemostasis by the PFA-100 analysis. Thromb Haemost 2000; 84: 93-7.
58 Pulcinelli FM, Pignatelli P, Celestini A. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Col Cardiol 2004; 43: 979-84.
59 Reist M, Roy-de Vos M, Montseny JP. et al. Very slow chiral inversion of clopidogrel in rats: A pharmacokinetic and mechanistic investigation. Drug Metab Dispos 2000; 28: 1405-10.
60 Ridker PM, Cook NR, Lee IM. et al. A randomised trial of low-dose aspirin in the primary preventionof cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
61 Sadiq PA, Puri A, Dixit M. et al. Profile and prevalence of aspirin resistance in Indian patients with coronary artery disease. Indian Heart J 2005; 57: 658-61.
62 Schrör K, Weber AA, Hohlfeld T. Clopidogrel resistance. Thromb Haemost 2004; 92: 229-31.
63 Second International Study of Infarct Survival Collaborative Group.. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
64 Serebruany VL, Midei MG, Malinin AI. et al. Atorvastatin does not affect the antiplatelet properties of clopidogrel in patients undergoing coronary stenting in randomized data from interaction of atorvastatin and clopidogrel (INTERACTION) trial. J Am Coll Cardiol 2003; 41: 302.
65 Serebruany VL, Steinhubl SR, Berger PB. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-51.
66 Steering Committee of the Physicians.. Health Study Research group: Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 1989; 352: 1366-8.
67 Steinhubl SR, Berger PB, Mann JT. CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomised controlled trial. JAMA 2002; 288: 2411-20.
68 Szczeklik A, Musial J, Undas A. et al. Aspirin resistance. J Thromb Haemost 2005; 3: 1655-62.
69 Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother 2005; 6: 2027-45.
70 Weber AA, Zimmermann KC, Meyer-Kirchrath J. et al. Cyclooxygenase-2 in human platelets as possible factor in aspirin resistance. Lancet 1999; 353: 900.
71 Yan Y, Phillips DR. Aspirin response and failure in diabetic patients with cardiovascular disease. Curr Opin Pharm 2005; 5: 190-7.